These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31183579)

  • 61. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
    Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis.
    Epperla N; Ahn KW; Litovich C; Ahmed S; Battiwalla M; Cohen JB; Dahi P; Farhadfar N; Farooq U; Freytes CO; Ghosh N; Haverkos B; Herrera A; Hertzberg M; Hildebrandt G; Inwards D; Kharfan-Dabaja MA; Khimani F; Lazarus H; Lazaryan A; Lekakis L; Murthy H; Nathan S; Nishihori T; Pawarode A; Prestidge T; Ramakrishnan P; Rezvani AR; Romee R; Shah NN; Sureda A; Fenske TS; Hamadani M
    J Hematol Oncol; 2019 Jan; 12(1):6. PubMed ID: 30630534
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The effect of G-CSF-stimulated donor marrow on engraftment and incidence of graft-versus-host disease in allogeneic bone marrow transplantation.
    Ji SQ; Chen HR; Xun CQ; Wang HX; Pan SP; Xiao MH
    Clin Transplant; 2001 Oct; 15(5):317-23. PubMed ID: 11678957
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma.
    Slavin S; Nagler A
    Ann Oncol; 1998; 9 Suppl 1():S31-9. PubMed ID: 9581239
    [TBL] [Abstract][Full Text] [Related]  

  • 65. New conditioning regimens for high risk marrow transplants.
    Jones RJ; Santos GW
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():15-7. PubMed ID: 2627618
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect.
    Dodero A; Spina F; Narni F; Patriarca F; Cavattoni I; Benedetti F; Ciceri F; Baronciani D; Scimè R; Pogliani E; Rambaldi A; Bonifazi F; Dalto S; Bruno B; Corradini P
    Leukemia; 2012 Mar; 26(3):520-6. PubMed ID: 21904377
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma.
    Kiss TL; Panzarella T; Messner HA; Meharchand J; Reddy V; Schimmer AD; Lipton JH
    Bone Marrow Transplant; 2003 Jan; 31(2):73-8. PubMed ID: 12621486
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
    Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
    Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen.
    Inamoto Y; Suzuki R; Kuwatsuka Y; Yasuda T; Takahashi T; Tsujimura A; Sugimoto K; Oba T; Terakura S; Atsuta Y; Murata M; Ito M; Kodera Y; Miyamura K
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):43-9. PubMed ID: 18158960
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation.
    Nagler A; Aker M; Or R; Naparstek E; Varadi G; Brautbar C; Slavin S
    Exp Hematol; 2001 Mar; 29(3):362-70. PubMed ID: 11274765
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors.
    Lundberg JH; Hansen RM; Chitambar CR; Lawton CA; Gottlieb M; Anderson T; Ash RC
    J Clin Oncol; 1991 Oct; 9(10):1848-59. PubMed ID: 1919635
    [TBL] [Abstract][Full Text] [Related]  

  • 73. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
    Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The next horizon now that everyone has a donor: Precision allogeneic transplantation.
    Jones RJ; Bacigalupo A
    Blood Rev; 2023 Nov; 62():100990. PubMed ID: 35908981
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Peripheral T-cell Lymphomas: Updates in Allogeneic Hematopoietic Stem Cell Transplantation.
    Huang WR; Liu DH
    Chin Med J (Engl); 2018 Sep; 131(17):2105-2111. PubMed ID: 30127221
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Nonmyeloablative allogeneic stem cell transplantation for non-hodgkin lymphoma.
    Khouri IF; Champlin RE
    Cancer J; 2012; 18(5):457-62. PubMed ID: 23006952
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Do CAR-T and Allogeneic Stem Cell Transplant Both Have a Place in Lymphoid Neoplasms?
    Martino M; Canale FA; Naso V; Porto G; Gerace D; Allegra A
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674573
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Use of checkpoint inhibitors in patients with lymphoid malignancies receiving allogeneic cell transplantation: a review.
    Bobillo S; Nieto JC; Barba P
    Bone Marrow Transplant; 2021 Aug; 56(8):1784-1793. PubMed ID: 33742152
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The place of allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma in the era of CAR-T-cell therapy.
    Castagna L; Bono R; Tringali S; Sapienza G; Santoro A; Indovina A; Tarantino V; Di Noto L; Maggio A; Patti C
    Front Med (Lausanne); 2022; 9():1072192. PubMed ID: 36561713
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Allogeneic transplantation after immunotherapy for relapsed/refractory non-Hodgkin lymphoma: a comparison with a historical cohort.
    Mariotti J; Zucchinetti C; Giordano L; De Philippis C; Mannina D; Sarina B; Taurino D; Carbon R; Santoro A; Bramanti S
    Cytotherapy; 2024 May; ():. PubMed ID: 38775776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.